PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 3, 2008, Pages 985-990

  Panigrahy, Dipak ^a   Kaipainen, Arja ^a   Huang, Sui ^a,d   Butterfield, Catherine E ^a   Barnés, Carmen M ^a   Fannon, Michael ^c   Laforme, Andrea M ^a,b   Chaponis, Deviney M ^a,b   Folkman, Judah ^a   Kieran, Mark W ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Fibrates; Inflammation; Microenvironment; Stroma

Indexed keywords

ENDOSTATIN; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; THROMBOSPONDIN 1; VASCULOTROPIN; FIBROBLAST GROWTH FACTOR 2; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA VASCULARIZATION; DRUG POTENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CORNEA; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM; ENDOTHELIUM CELL; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; NEOPLASM; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALIA; MUS;

ANIMALS; CELL LINE, TUMOR; CORNEA; ENDOTHELIAL CELLS; ENDOTHELIUM; FIBROBLAST GROWTH FACTOR 2; HUMANS; LIGANDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; PPAR ALPHA; PROCETOFEN;

EID: 38949145780     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0711281105     Document Type: Article

References (39)

1. Lefebvre P, Chinetti G, Fruchart JC, Staels B (2006) Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 116:571-580.
2. Devchand PR, et al. (1996) The PPARα-leukotriene B4 pathway to inflammation control. Nature 384:39-43.
3. Peters JM, Cattley RC, Gonzalez FJ (1997) Role of PPARα in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy 14,643. Carcinogenesis 18:2029-2033.
4. Michalik L, Desvergne B, Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4:61-70.
5. Collett GP, et al. (2000) Peroxisome proliferator-activated receptorα is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res 6:3241-3248.
6. Suchanek KM, et al. (2002) Peroxisome proliferator-activated receptorα and the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog 34:165-171.
7. Tanaka T, et al. (2001) Ligands for peroxisome proliferator-activated receptorsα and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 61:2424-2428.
8. Maggiora M, et al. (2004) An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int J Cancer 112:909-919.
9. Saidi SA, Holland CM, Charnock-Jones DS, Smith SK (2006) In vitro and in vivo effects of the PPARα agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 5:13.
10. Thuillier P, et al. (2000) Activators of peroxisome proliferator-activated-α partially inhibit mouse skin tumor promotion. Mol Carcinog 29:134-142.
11. Grabacka M, et al. (2004) Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res 296:54-58.
12. Grabacka M, Plonka PM, Urbanska K, Reiss K (2006) Peroxisome proliferator-activated receptorα activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res 12:3028-3036.
13. Yokoyama Y, et al. (2007) Clofibric acid, a peroxisome proliferator-activated receptorα ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther 6:1379-1386.
14. Pozzi A, et al. (2007) Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem 282:17685-17695.
15. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J (1999) PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125-3131.
16. Berger J, Moller DE (2002) Mechanism of action of PPARs. Annu Rev Med 53:409-435.
17. Goetze S, et al. (2002) PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 293:1431-1437.
18. Varet J, et al. (2003) Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 60:810-819.
19. Meissner M, et al. (2004) PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 94:324-332.
20. Kasai T, Miyauchi K, Yokoyama T, Aihara K, Daida H (2006) Efficacy of peroxisome proliferative activated receptor (PPAR)-α ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. Atherosclerosis 188:274-280.
21. Blann AD, Belgore FM, Constans J, Conri C, Lip GY (2001) Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 87:1160-1163.
22. Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: From orphan receptors to drug discovery. J Med Chem 43:527-550.
23. Grau R, Punzon C, Fresno M, Iniguez MA (2006) Peroxisome-proliferator- activated receptorα agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochem J 395:81-88.
24. Kaipainen A, et al. (2007) PPARα deficiency in inflammatory cells suppresses tumor growth. PLoS ONE 2:e260.
25. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.
26. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867.
27. Niho N, et al. (2003) Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 63:6090-6095.
28. Pighetti GM, et al. (2001) Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res 21:825-829.
29. Panigrahy D, et al. (2002) PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923-932.
30. Piqueras L, et al. (2007) Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 27:63-69.
31. Moraes LA, Piqueras L, Bishop-Bailey D (2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110:371-385.
32. Abdollahi A, et al. (2004) Endostatin's antiangiogenic signaling network. Mol Cell 13:649-663.
33. Moulton KS, et al. (1999) Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99:1726-1732.
34. Tordjman K, et al. (2001) PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 107:1025-1034.
35. Duez H, et al. (2002) Reduction of atherosclerosis by the peroxisome proliferator-activated receptorα agonist fenofibrate in mice. J Biol Chem 277:48051-48057.
36. Dellavalle RP, Nicholas MK, Schilling LM (2003) Melanoma chemoprevention: A role for statins or fibrates? Am J Ther 10:203-210.
37. Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M (2002) Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 47:672-684.
38. Kieran MW, et al. (2005) A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27:573-581.
39. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436.